Novartis arbetar för att skapa mervärde för patienter och våra samarbetspartners inom sjukvården. Vi vill påverka människors liv i en positiv riktning genom att upptäcka, utveckla och marknadsföra nya produkter för att bota sjukdomar och förbättra människors livskvalitet.

  • Studier om migrän
  • Studier om CGRP
  • Studier om erenumab


Studier om migrän

One-year prevalence of migraine in Sweden: a population-based study in adults
Dahlöf C1, Linde M, Cephalalgia. 2001 Jul;21(6):664-71.

The global burden of headache
Saylor D, Steiner T.J, Semin Neurol. 2018 Apr;38(2):182-190. Epub 2018 May 23.

 Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, Lancet. 2016 Oct 8;388(10053):1545-1602.

Studier om CGRP

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
Edvinsson L, Br J Clin Pharmacol. 2015 Aug; 80(2): 193–199.

The Journey to Establish CGRP as a Migraine Target: A Retrospective View
Edvinsson L, Headache. 2015 Oct;55(9):1249-55. doi: 10.1111/head.12656. Epub 2015 Sep 14.

Calcitonin Gene-Related Peptide (CGRP) and Migraine
Durham P.L, Headache. 2006 Jun; 46(Suppl 1): S3–S8.

CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson L, Haanes K.A, Warfvinge K, Krause D.N, Nature Reviews Neurologyvolume 14, pages338–350 (2018).

CGRP: Sensory neuropeptide with multiple neurologic implications
Benarroch E.E, Neurology. July 19, 2011; 77 (3).

Calcitonin gene-related peptide (CGRP): a new target for migraine
Russo AF, Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/annurev-pharmtox-010814-124701. Epub 2014 Oct 8.

Studier om erenumab

A Controlled Trial of Erenumab for Episodic Migraine
Goadsby P.J, Reuter U, Hallström Y, Broessner G, Bonner J.H, Zhang F, Sapra S, Picard H, Mikol D.D, Lenz R.A, N Engl J Med 2017; 377:2123-2132.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Reuter U et al,The Lancet, Nov 2018, issue 10161, P2280-2287.

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Tepper S et al, The Lancet, Jun 2017, issue 6, P425-434.

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study
Ashina M et al, Neurology. 2017 Sep 19;89(12):1237-1243.

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Shi L et al, Journal of Pharmacology and Experimental Therapeutics January 2016, 356 (1) 223-231.

Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week open-label study
Tepper S J et al. Cephalalgia 2020 vol 40(6) 543-553

Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial
Ashina M et al. European journal of neurology, Nov 2020. DOI: 10.1111/ene.14715 

Safety & Tolerability evalutation of Erenumab for the preventive treatment of migraine
Deligianni C I et al, Informa, Expert Opinion on Drug Safdety, Aug 2021 DOI: 10.1080/14740338.3031.1933841 


Betygsätt sidan
SE2112214315 (21 december 2021)

Ask Speakers


Medical Information Request